Scancell Holdings Plc (LON:SCLP) said the European Patent Office intends to grant the company’s patent application for the Moditope immunotherapy platform.
Once formally granted the patent will provide protection for Scancell’s pipeline of Moditope vaccines that could help revolutionise the way cancer is treated.
READ: Scancell-led team short-listed for award
The patent will cover all major areas in Europe, while similar filings have been made in Australia, Brazil, Canada, China, Hong Kong, Japan, South Korea, South Africa and the US.
"By confirming its intention to grant this patent application, the European Patent Office has continued to uphold the validity of Scancell's expanding patent estate,” said chief executive Cliff Holloway.
“This is a key case for the company as we progress development of our Moditope platform and provides further protection for Scancell's innovative cancer vaccine technologies."